Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 7/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9252347 | 0.88 | NPSR1 (0.58) | NPSR1PTPN1F10HDAC8NR1D1 | |
| SCHEMBL1052393 | 0.87 | NPSR1 (0.62) | NPSR1PTPN1F10 | |
| SCHEMBL30314166 | 0.87 | NPSR1 (0.62) | NPSR1PTPN1F10 | |
| SCHEMBL3629346 | 0.87 | NPSR1 (0.62) | NPSR1PTPN1F10 | |
| SCHEMBL29401156 | 0.87 | NPSR1 (0.62) | NPSR1PTPN1F10 | |
| SCHEMBL14862925 | 0.87 | NPSR1 (0.62) | NPSR1PTPN1F10 | |
| SCHEMBL204265 | 0.86 | MMP2 (0.51) | NPSR1PTPN1F10PREPMITF | |
| SCHEMBL8225741 | 0.86 | MMP2 (0.51) | NPSR1PTPN1F10PREPMITF | |
| SCHEMBL204264 | 0.86 | MMP2 (0.51) | NPSR1PTPN1F10PREPMITF | |
| SCHEMBL6649282 | 0.86 | NPSR1 (0.56) | NPSR1PTPN1F10HDAC8NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP | 2013-11-14 | — | — | US | disclosed |
| US-8513433-B2 | Small molecule inhibitors of PARP activity | ANGION BIOMEDICA CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011002520-A2 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | PARP1, PARP11, PARP15 | NPSR1 3404/4885PTPN1 4744/4885F10 1660/4885 |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | PARP1, PARP11, PARP15 | NPSR1 3404/4885PTPN1 4744/4885F10 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.